(Q37601293)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

review article

1 reference

title

Ipilimumab in the treatment of metastatic melanoma: management of adverse events (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Soldano Ferrone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Giuseppina Della Vittoria Scarpati

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Celeste Fusciello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Chiara Carlomagno

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Stefano Pepe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

19 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

published in

OncoTargets and Therapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

203-209

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

8 March 2020

start time

1 February 2014

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Management of immune-related adverse events and kinetics of response with ipilimumab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Profile of ipilimumab and its role in the treatment of metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

2 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933725

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24570590

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sarcoidosis induced by interferon-α in melanoma patients: incidence, clinical manifestations, and management strategies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24570590

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/OTT.S57335

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PubMed publication ID

24570590

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24570590%20AND%20SRC:MED&resulttype=core&format=json